Emerging small molecular inhibitors as targeted therapies for high-risk acute myeloid leukemias.

Kieran D SahasrabudheMary AlbrethsenAlice S Mims

Published in: Expert review of hematology (2023)

There are several small molecule inhibitors that have demonstrated promise in these high-risk AML subsets. Longer follow up and ongoing investigation is needed to continue to optimize therapy for patients with high-risk AML.

Keyphrases

acute myeloid leukemia
small molecule
liver failure
respiratory failure
big data
machine learning
acute lymphoblastic leukemia
immune response
single molecule
deep learning
artificial intelligence
mechanical ventilation